PCOS in Your 30s: Insulin, Androgens, and the Diagnosis Most Women Get Wrong
PCOS in Your 30s: Insulin, Androgens, and the Diagnosis Most Women Get Wrong
Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, affecting between eight and thirteen percent of the population by current estimates. It is also one of the most misunderstood diagnoses in medicine, in two opposite directions. Many women have it and do not know. Many women are told they have it when they do not.
The clinical picture varies. The patient who presents with irregular cycles, acne, weight that resists effort, hair on the chin and lower abdomen, and elevated androgens on labs is recognizable to any physician. The patient with regular cycles, no obvious hirsutism, normal-range testosterone, but ovarian morphology consistent with PCOS on ultrasound is not — and is often dismissed. The patient who is lean, cycling regularly, but with an underlying insulin resistance pattern and elevated free testosterone is rarely diagnosed at all. All three of these patients can have PCOS by the Rotterdam criteria. All three benefit from intervention.
The diagnosis matters because PCOS is not just a fertility issue. It is a metabolic and inflammatory condition with lifelong implications for cardiovascular health, type 2 diabetes risk, body composition, mood, and longevity.
What PCOS Actually Is
The Rotterdam criteria, established in 2003 and still the international standard, require the presence of at least two of three findings to make the diagnosis:
- Oligoovulation or anovulation (irregular cycles, prolonged intercycle intervals, or absence of ovulation).
- Clinical or biochemical hyperandrogenism (acne, hirsutism, androgenic alopecia, or elevated total or free testosterone).
- Polycystic ovarian morphology on ultrasound (multiple small follicles arranged peripherally, often described as a string-of-pearls appearance).
Two of three is enough. Critically, all three are not required, and the presence of polycystic ovaries on ultrasound is neither necessary nor sufficient. Many women with normal ovarian morphology have PCOS. Many women with polycystic-appearing ovaries on ultrasound do not.
Other causes of irregular cycles and hyperandrogenism — thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, Cushing’s syndrome, androgen-secreting tumours — must be excluded before the diagnosis is made.
The Insulin Connection
The single most important pathophysiological insight in PCOS is the central role of insulin resistance.
Roughly seventy percent of women with PCOS have demonstrable insulin resistance, often well before fasting glucose or HbA1c shows abnormality. Elevated insulin acts on the ovary to promote androgen production. Insulin also suppresses sex hormone binding globulin (SHBG), which increases the free, biologically active fraction of circulating testosterone. The result is a self-reinforcing loop: insulin resistance drives androgen excess, and androgen excess worsens metabolic dysfunction.
This explains why the metabolic phenotype tracks PCOS so closely. Women with PCOS are at significantly elevated risk of type 2 diabetes, hepatic steatosis, dyslipidemia, hypertension, and cardiovascular events compared to women without the diagnosis.
It also explains why a proper PCOS workup measures insulin and not just glucose. Fasting glucose may be normal for years while fasting insulin is climbing. HOMA-IR — calculated from fasting glucose and fasting insulin — is the simplest validated index of insulin resistance and should be standard in any PCOS evaluation.
A separate but related discussion of why fasting insulin is the single most useful metabolic test, and why it is not yet routine in Canadian primary care, appears in Fasting Insulin: The Test That Should Be Routine.
The Lean PCOS Phenotype
The classical mental image of PCOS is the patient who carries excess weight, has visible hirsutism, and presents with markedly irregular cycles. That image is not wrong, but it captures only part of the population.
A meaningful fraction of women with PCOS — by some estimates twenty to thirty percent — are lean. They do not meet BMI criteria for overweight or obesity. They may cycle regularly or near-regularly. Their total testosterone may be at the upper end of the normal range rather than overtly elevated. Their fasting glucose is normal. The conventional screen finds no abnormality.
What these patients often have is an elevated free testosterone with low SHBG, fasting insulin that is climbing into the upper range, an ApoB or LDL pattern that is drifting unfavourably, and symptoms — adult acne, scalp hair thinning, mood changes, mid-cycle pelvic discomfort — that are real but easy to dismiss.
This is the patient who arrives a decade later with established type 2 diabetes, more entrenched metabolic dysfunction, and an opportunity for early intervention long since past. The diagnosis matters because the trajectory is changeable.
What Treatment Actually Looks Like
Treatment of PCOS in conventional practice often defaults to combined oral contraceptives, which mask symptoms by suppressing ovarian function and increasing SHBG. The cycles regulate. The acne improves. The hirsutism slows. None of the underlying metabolic dysfunction is addressed.
For some patients — particularly those whose primary concern is symptom management rather than fertility — this is a reasonable choice with appropriate informed consent. For many, it is treating the smoke without addressing the fire.
A more comprehensive PCOS plan includes several components.
Metabolic correction. Insulin sensitivity is the central target. Resistance training, cardiovascular fitness development, adequate protein intake, and sleep restoration are foundational. Inositol — myo-inositol and D-chiro-inositol in approximately a forty-to-one ratio — has clinical trial evidence for improving insulin sensitivity, ovulatory function, and cycle regularity in PCOS, with a favourable safety profile.
Pharmacotherapy when appropriate. Metformin remains useful in PCOS, particularly when fasting insulin is significantly elevated or HbA1c is approaching prediabetic range. GLP-1 receptor agonists have growing evidence in PCOS for weight management, ovulatory restoration, and metabolic improvement; the physician’s framework for GLP-1 therapy applies here as elsewhere.
Hormonal optimization. Where androgen excess persists despite metabolic improvement, anti-androgenic strategies — spironolactone, in some cases — may be appropriate. In perimenopausal patients with PCOS, the menopause transition often paradoxically improves the syndrome as estrogen and androgen levels both decline; this is a teachable moment, not a discharge from monitoring.
Cardiometabolic surveillance. PCOS warrants lifelong monitoring of fasting insulin, HbA1c, lipids with ApoB, blood pressure, hepatic function, and body composition. The risk does not end at menopause. The condition shifts in expression but the metabolic phenotype persists.
The Vis Viva framework maps cleanly onto this. Sensus tracks symptom burden — cycle regularity, skin and hair, mood, energy. Pulsus tracks the labs that define the disease and predict its long-term course. Virtus tracks the functional capacity that reflects the success of metabolic intervention.
What to Ask Your Physician
If you suspect PCOS, or if you have been told you have it and want a second opinion, several questions move the conversation forward.
Have my fasting insulin and HOMA-IR been measured, in addition to fasting glucose and HbA1c? Have free testosterone and SHBG been measured, not just total testosterone? Have other causes of irregular cycles and hyperandrogenism been ruled out — thyroid, prolactin, 17-hydroxyprogesterone? Is the treatment plan addressing insulin sensitivity and metabolic risk, or only managing symptoms?
The answers, in aggregate, separate a PCOS that has been treated from a PCOS that has been understood.
Continue Reading
If you found this useful, these related articles may deepen your understanding:
- How Insulin Resistance Is Quietly Destroying Your Testosterone
- Fasting Insulin: The Test That Should Be Routine
- Metabolic Syndrome in Your 40s
Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario compounding pharmacy partner Trutina. To learn more or book a virtual consultation, visit manussolis.ca.
Continue Reading